ClinicalTrials.gg
CompletedNCT04053387Updated Aug 6, 2025Results posted

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

A Phase 3 interventional study of tapinarof cream, 1% in Plaque Psoriasis, sponsored by Organon and Co. Completed at 104 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
763
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
2nd of 19
763 · median 58
Started
2019
with 3 others
Phase 3
5 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
7 of 19
Organon and Co

Among the 19 studies testing tapinarof in Psoriasis, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 8th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.

Read the detailed description

At the completion of the Week-12 visit of the pivotal study (Baseline [Day 1] in this study), all eligible subjects will be offered enrollment in the long-term extension study. Study visits during the treatment period for all subjects will occur every 4 weeks (± 3 days). The total duration of study participation will be approximately 44 weeks.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Tapinarof
  • plaque psoriasis,
  • adult
  • phase 3
  • topical
  • open-label
  • efficacy
  • safety
  • psoriasis
  • long-term
  • therapeutic aryl hydrocarbon receptor modulating agent
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed the 12-week treatment period in 1 of the 2 parent studies (Study DMVT-505-3001 or Study DMVT-505-3002);
  2. Male and female subjects
  3. Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance while on the study, and for at least 4 weeks after the last exposure to study treatment
  4. Capable of giving written

Exclusion criteria

Exclusion Criteria:

  1. Used a prohibited concomitant product or procedure to treat psoriasis during parent study
  2. Had a serious adverse event (SAE) that was potentially related to treatment or experienced an adverse event (AE) that led to permanent discontinuation of treatment in the parent study
  3. History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's completion of the study
  4. Known to tapinarof
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
763 participants (actual)

Study arms

  • Experimental
    Tapinarof (DMVT-505) Cream Group

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 received treatment with tapinarof cream, 1% until they achieve a PGA = 0, at which time treatment was discontinued and subjects were monitored for durability of response (remittive response). If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved. This treatment and re treatment pattern of use was continued until the end of the study

    Drug: tapinarof cream, 1%

Interventions

  • Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score

    Also known as: DMVT-505

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events and Serious Adverse Events

    All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study. All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

    Time frame: Baseline to 44 weeks

  2. Frequency of Adverse Events and Serious Adverse Events

    All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE. All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

    Time frame: Baseline to 44 weeks

  3. Number of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital Signs

    The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in chemistry and hematology parameters for individual subjects were assessed for clinical relevance. The number of subjects with clinically significant changes from baseline in laboratory values was assessed for clinical relevance.

    Time frame: Baseline to 40 weeks

  4. Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the median time for subjects entering with a PGA = 0 to first worsening (PGA ≥ 2) while off therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Baseline to 44 weeks

  5. Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the number of subjects who entered the extension study with a PGA ≥ 1 and achieved complete disease clearance (PGA=0) while on therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

    Time frame: Baseline to 44 weeks

  6. Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the number of these subjects who entered the study with a PGA≥ 2 and achieved a PGA of 0 or 1 (clear or almost clear) while on therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

    Time frame: Baseline to 44 weeks

  7. Remittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear)

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. This outcome measure assesses the number of these subjects entering the study with a PGA= 0 who experienced worsening (PGA ≥ 2) while off therapy at least once during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Baseline to 44 weeks

  8. Change From Baseline in %BSA Affected

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage \[Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)\]. The total %BSA involved was estimated = % involvement

    Time frame: Baseline to 40 weeks

  9. Percent Change From Baseline in %BSA Affected

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage \[Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)\]. The total %BSA involved was estimated = % involvement

    Time frame: Baseline to 40 weeks

  10. Mean Duration (Days) of Treatment Course

    Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued tapinarof until they achieved a PGA = 0, at which time treatment was discontinued. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. Mean duration (days) of treatment episode = time (days) from date of each PGA ≥ 2 (or PGA ≥ 1 for the first episode) to 1 day before each subsequent PGA = 0. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

    Time frame: Baseline to 40 weeks

  11. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in PASI score in all subjects, including those on and those off therapy. The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

    Time frame: Baseline to 40 weeks

  12. Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in PASI score in all subjects, including those on and those off therapy. The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

    Time frame: Baseline to 40 weeks

  13. Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy. The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.

    Time frame: Baseline to 40 weeks

  14. Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)

    Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses % change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy. The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0.

    Time frame: Baseline to 40 weeks

07

Results

Posted Aug 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Started763
Completed531
Not completed232

Outcome measures

PrimaryNumber of Subjects With Adverse Events and Serious Adverse Events

All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study. All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

Time frame:
Baseline to 44 weeks
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events and Serious Adverse Events
ParticipantsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Adverse Events474
Serious Adverse Events19
PrimaryFrequency of Adverse Events and Serious Adverse Events

All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of the pivotal Phase 3 studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE. All SAEs were deemed unrelated to treatment with tapinarof cream, 1%.

Time frame:
Baseline to 44 weeks
Reported as:
Number · events
Frequency of Adverse Events and Serious Adverse Events
eventsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Adverse Events1190
Serious Adverse Events21
PrimaryNumber of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital Signs

The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in chemistry and hematology parameters for individual subjects were assessed for clinical relevance. The number of subjects with clinically significant changes from baseline in laboratory values was assessed for clinical relevance.

Time frame:
Baseline to 40 weeks
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Meaningful Changes From Baseline in Clinical Laboratory Values and Vital Signs
ParticipantsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Clinically Meaningful changes in hematology0
Clinically meaningful changes in chemistry0
Clinically meaningful changes in urinalysis0
Clinically meaningful changes in pulse rate7
Clinically meaningful changes in systolic blood pressure6
Clinically meaningful changes in diastolic blood pressure16
PrimaryRemittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the median time for subjects entering with a PGA = 0 to first worsening (PGA ≥ 2) while off therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Time frame:
Baseline to 44 weeks
Reported as:
Median · days from baseline visit
Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)
days from baseline visitContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Remittive Effect of Treatment Success in Pivotal: Median Time to First Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE PGA = 0 (Clear)115 (85.0 to 168.0)
PrimaryComplete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the number of subjects who entered the extension study with a PGA ≥ 1 and achieved complete disease clearance (PGA=0) while on therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Time frame:
Baseline to 44 weeks
Reported as:
Count of participants · Participants
Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)
ParticipantsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance PGA =0 (Clear) While on Therapy for Subjects Entered LTE PGA ≥ 1 (Almost Clear)233
PrimaryResponse During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued treatment with tapinarof until they achieved a PGA = 0, at which time treatment was discontinued and subjects were monitored for remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This outcome measure assesses the number of these subjects who entered the study with a PGA≥ 2 and achieved a PGA of 0 or 1 (clear or almost clear) while on therapy during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Time frame:
Baseline to 44 weeks
Reported as:
Count of participants · Participants
Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)
ParticipantsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Response During LTE: Number of Subjects Achieving PGA =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With PGA ≥ 2 (Mild)302
PrimaryRemittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear)

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. This treatment and re-treatment pattern of use was continued until the end of the study. This outcome measure assesses the number of these subjects entering the study with a PGA= 0 who experienced worsening (PGA ≥ 2) while off therapy at least once during this extension study. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe.

Time frame:
Baseline to 44 weeks
Reported as:
Count of participants · Participants
Remittive Effect of Treatment Success: Number of Subjects Experiencing Worsening (PGA ≥ 2) While Off Therapy for Subjects Who Entered LTE With a PGA = 0 (Clear)
ParticipantsContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Number of subjects entering with PGA=0 who experienced PGA ≥ 2 at least 1 time during the study60
Number of subjects entering with PGA=0 who never experienced PGA ≥ 2 throughout the study19
PrimaryChange From Baseline in %BSA Affected

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage \[Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)\]. The total %BSA involved was estimated = % involvement

Time frame:
Baseline to 40 weeks
Reported as:
Mean · percentage of BSA affected
Change From Baseline in %BSA Affected
percentage of BSA affectedContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Change From Baseline in %BSA Affected-2.03 ± 4.848
PrimaryPercent Change From Baseline in %BSA Affected

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. BSA affected was estimated by the handprint method, where the full palmar hand of the subject represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints (hp) with percentage \[Head and neck = 10% (10 hp), upper extremities = 20% (20 hp), Trunk (including axillae and groin) = 30% (30 hp), lower extremities (including buttocks) = 40% (40 hp)\]. The total %BSA involved was estimated = % involvement

Time frame:
Baseline to 40 weeks
Reported as:
Mean · percentage change
Percent Change From Baseline in %BSA Affected
percentage changeContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Percent Change From Baseline in %BSA Affected-18.48 ± 149.908
PrimaryMean Duration (Days) of Treatment Course

Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study. Subjects entering with a PGA ≥ 1 continued tapinarof until they achieved a PGA = 0, at which time treatment was discontinued. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re-initiated and continued until a PGA = 0 was achieved. Mean duration (days) of treatment episode = time (days) from date of each PGA ≥ 2 (or PGA ≥ 1 for the first episode) to 1 day before each subsequent PGA = 0. The PGA is an assessment of a subject's psoriasis using a static 5-point scale to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, where 0 = clear, 1= almost clear, 2 = mild, 3 = moderate, and 4 = severe. Higher PGA scores represent more severe disease.

Time frame:
Baseline to 40 weeks
Reported as:
Mean · days
Mean Duration (Days) of Treatment Course
daysContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Mean Duration (Days) of Treatment Course172.9 ± 102.17
PrimaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in PASI score in all subjects, including those on and those off therapy. The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

Time frame:
Baseline to 40 weeks
Reported as:
Mean · scores on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
scores on a scaleContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score-1.80 ± 4.334
PrimaryPercent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in PASI score in all subjects, including those on and those off therapy. The PASI scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). Overall PASI = the sum of (individual scores x by a weighted factor for each body region).

Time frame:
Baseline to 40 weeks
Reported as:
Mean · percentage change
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
percentage changeContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score-11.90 ± 151.684
PrimaryChange From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy. The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.

Time frame:
Baseline to 40 weeks
Reported as:
Mean · scores on a scale
Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)
scores on a scaleContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)-2.0 ± 4.31
PrimaryPercent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)

Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses % change from baseline in disease impact on daily activities, as measured by the DLQI, in all subjects including those on and those off therapy. The DLQI is a 10-item PRO measure that assesses the extent to which the skin condition has affected the subject's quality of life over the past week, including 6 domains (daily activities, personal relationships, symptoms and feelings, leisure, work/school, and treatment). The total score (0-30) is the sum of 10 questions with each ranging from 0 to 3. The scoring of each question is as follows: Very much= 3, A lot=2, A little = 1, Not at all = 0, Not relevant = 0, Question unanswered = 0.

Time frame:
Baseline to 40 weeks
Reported as:
Mean · percentage change
Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)
percentage changeContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Percent Change From Baseline in Disease Impact on Daily Activities, as Measured by the Dermatology Life Quality Index (DLQI)-37.1 ± 121.35

Adverse events

Collected over subject duration: 40 weeks of treatment and a 4 week, safety follow up period Overall duration of study: 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score1/763 (0.1%)19/763 (2.5%)204/763 (26.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
PancreatitisGastrointestinal disorders2/763
Road Traffic AccidentInjury, poisoning and procedural complications2/763
ArrhythmiaCardiac disorders1/763
Myocardial InfarctionCardiac disorders1/763
Pericardial effusionCardiac disorders1/763
AppendicitisInfections and infestations1/763
DiverticulitisInfections and infestations1/763
Pelvic inflammatory diseaseInfections and infestations1/763
PneumoniaInfections and infestations1/763
Tooth abscessInfections and infestations1/763
Most frequent other events
Most frequent other events
EventContinuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
FolliculitisInfections and infestations173/763
Dermatitis contactSkin and subcutaneous tissue disorders42/763

Baseline characteristics

Age, Continuous
Age, Continuous(years)Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Mean50.7 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Female315
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
Hispanic or Latino117
Not Hispanic or Latino641
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score
American Indian or Alaska Native4
Asian51
Native Hawaiian or Other Pacific Islander2
Black or African American39
White643
More than one race18
Unknown or Not Reported6
08

Study locations

104 sites
  • Dermavant Investigative Site
    Birmingham, Alabama 35205, United States
  • Dermavant Investigative Site
    Phoenix, Arizona 85032, United States
  • Dermavant Investigative Site
    Bryant, Arkansas 72022, United States
  • Dermavant Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Dermavant Investigative Site
    Fountain Valley, California 92708, United States
  • Dermavant Investigative Site
    Fremont, California 94538, United States
  • Dermavant Investigative Site
    Fresno, California 93720, United States
  • Dermavant Investigative Site
    Los Angeles, California 90033, United States
  • Dermavant Investigative Site
    Los Angeles, California 90045, United States
  • Dermavant Investigative Site
    Northridge, California 91324, United States
  • Dermavant Investigative Site
    Oceanside, California 92056, United States
  • Dermavant Investigative Site
    San Diego, California 92123, United States
  • Dermavant Investigative Site
    Santa Ana, California 92701, United States
  • Dermavant Investigative Site
    Santa Monica, California 90404, United States
  • Dermavant Investigative Site
    Denver, Colorado 80210, United States
  • Dermavant Investigative Site
    Cromwell, Connecticut 06416, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33431, United States
  • Dermavant Investigative Site
    Boynton Beach, Florida 33437, United States
  • Dermavant Investigative Site
    Hialeah, Florida 33016, United States
  • Dermavant Investigative Site
    Margate, Florida 33063, United States
  • Dermavant Investigative Site
    Miami, Florida 33144, United States
  • Dermavant Investigative Site
    Miramar, Florida 33027, United States
  • Dermavant Investigative Site
    Boise, Idaho 83713, United States
  • Dermavant Investigative Site
    Rolling Meadows, Illinois 60008, United States
  • Dermavant Investigative Site
    Evansville, Indiana 47714, United States
  • Dermavant Investigative Site
    Indianapolis, Indiana 46250, United States
  • Dermavant Investigative Site
    New Albany, Indiana 47150, United States
  • Dermavant Investigative Site
    Plainfield, Indiana 46168, United States
  • Dermavant Investigative Site
    Overland Park, Kansas 66215, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40217, United States
  • Dermavant Investigative Site
    Owensboro, Kentucky 42303, United States
  • Dermavant Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Dermavant Investigative Site
    New Orleans, Louisiana 70115, United States
  • Dermavant Investigative Site
    Rockville, Maryland 20850, United States
  • Dermavant Investigative Site
    Boston, Massachusetts 02115, United States
  • Dermavant Investigative Site
    Bay City, Michigan 48706, United States
  • Dermavant Investigative Site
    Clarkston, Michigan 48346, United States
  • Dermavant Clinical Site
    Detroit, Michigan 48202, United States
  • Dermavant Investigational Site
    Detroit, Michigan 48202, United States
  • Dermavant Investigative Site
    Fort Gratiot, Michigan 48059, United States
  • Dermavant Investigative Site
    Warren, Michigan 48088, United States
  • Dermavant Investigative Site
    Fridley, Minnesota 55432, United States
  • Dermavant Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Dermavant Investigative Site
    Omaha, Nebraska 68144, United States
  • Dermavant Clinical Site
    Las Vegas, Nevada 89148, United States
  • Dermavant Investigative Site
    Las Vegas, Nevada 89148, United States
  • Dermavant Investigative Site
    East Windsor, New Jersey 08520, United States
  • Dermavant Investigative Site
    Hackensack, New Jersey 07601, United States
  • Dermavant Investigative Site
    Verona, New Jersey 07044, United States
  • Dermavant Clinical Site
    Brooklyn, New York 11203, United States
  • Dermavant Investigative Site
    Kew Gardens, New York 11374, United States
  • Dermavant Investigative Site
    New York, New York 10029, United States
  • Dermavant Investigative Site
    Rochester, New York 14623, United States
  • Dermavant Investigative Site
    Stony Brook, New York 11790, United States
  • Dermavant Clinical Site
    Watertown, New York 13601, United States
  • Dermavant Investigative Site
    Cary, North Carolina 27518, United States
  • Dermavant Investigative Site
    High Point, North Carolina 27262, United States
  • Dermavant Investigative Site
    Wilmington, North Carolina 28405, United States
  • Dermavant Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Dermavant Investigative Site
    Beachwood, Ohio 44122, United States
  • Dermavant Investigative Site
    Bexley, Ohio 43209, United States
  • Dermavant Investigative Site
    Norman, Oklahoma 73071, United States
  • Dermavant Investigate Site
    Norman, Oklahoma 73072, United States
  • Dermavant Investigative Site
    Norman, Oklahoma 73072, United States
  • Dermavant Clinical Site
    Gresham, Oregon 97030, United States
  • Dermavant Investigative Site
    Portland, Oregon 97210, United States
  • Dermavant Investigative Site
    Portland, Oregon 97223, United States
  • Dermavant Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Dermavant Investigative Site
    Johnston, Rhode Island 02919, United States
  • Dermavant Investigative Site
    Charleston, South Carolina 29407, United States
  • Dermavant Investigative Site
    Nashville, Tennessee 37215, United States
  • Dermavant Investigative Site
    Arlington, Texas 76011, United States
  • Dermavant Clinical Site
    Bellaire, Texas 77401, United States
  • Dermavant Investigative Site
    College Station, Texas 77845, United States
  • Dermavant Investigative Site
    Dripping Springs, Texas 78620, United States
  • Dermavant Investigative Site
    Houston, Texas 77004, United States
  • Dermavant Clinical Site
    Houston, Texas 77030, United States
  • Dermavant Investigative Site
    Pflugerville, Texas 78660, United States
  • Dermavant Investigative Site
    Plano, Texas 75024, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78229, United States
  • Dermavant Investigative Site
    Webster, Texas 77598, United States
  • Dermavant Investigative Site
    West Jordan, Utah 84088, United States
  • Dermavant Investigative Site
    Norfolk, Virginia 23502, United States
  • Dermavant Investigative Site
    Spokane, Washington 99202, United States
  • Dermavant Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Dermavant Investigative Site
    Surrey, Bristish Columbia V3V 0C6, Canada
  • Dermavant Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Dermavant Investigative Site
    Ajax, Ontario L1S 7K8, Canada
  • Dermavant Clinical Site
    Burlington, Ontario L7L 6W6, Canada
  • Dermavant Investigative Site
    Cobourg, Ontario K9A 0Z4, Canada
  • Dermavant Investigative Site
    Etobicoke, Ontario M8X 1Y9, Canada
  • Dermavant Investigative Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Dermavant Clinical Site
    Hamilton, Ontario L8S 1G5, Canada
  • Dermavant Investigative Site
    Markham, Ontario L3P 1X2, Canada
  • Dermavant Clinical Site
    Markham, Ontario L3P 1X3, Canada
  • Dermavant Investigative Site
    North Bay, Ontario P1B 3Z7, Canada
  • Dermavant Investigative Site
    Oakville, Ontario L6J 7W5, Canada
  • Dermavant Investigative Site
    Ottawa, Ontario K2C 3N2, Canada
  • Dermavant Investigative Site
    Richmond Hill, Ontario L4C 9M7, Canada

Showing the first 100 of 104 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gold LS, Bruno MJ, Lewitt GM, Hebert AA. Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. J Dermatolog Treat. 2025 Dec;36(1):2517388. doi: 10.1080/09546634.2025.2517388. Epub 2025 Jul 2. PubMed 40600584 ↗
  • Desai SR, Stein Gold L, Cameron MC, Golant A, Lewitt GM, Bruno MJ, Martin G, Brown PM, Rubenstein DS, Butners V, Tallman AM. Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials. Dermatol Ther (Heidelb). 2023 Oct;13(10):2443-2460. doi: 10.1007/s13555-023-01008-9. Epub 2023 Sep 11. PubMed 37697121 ↗
  • Grossmann MC, Pixley JN, Feldman SR. A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis. Ann Pharmacother. 2024 Jan;58(1):76-85. doi: 10.1177/10600280231164775. Epub 2023 Apr 19. PubMed 37076998 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Apr 2021, 19 months.

Results were first posted in Aug 2022, 1 year 4 months after primary completion. A results delay was requested in Jun 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 19 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Aug 12, 2019
StartActual
Aug 13, 2019
Primary completionActual
Apr 6, 2021
CompletionActual
Apr 6, 2021
Results delay requested
Jun 22, 2021
Results first posted
Aug 8, 2022
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04053387
Lead sponsor
Organon and Co
Collaborators
IQVIA Biotech
Responsible party
Sponsor
First posted
Aug 12, 2019
Start date
Aug 13, 2019
Primary completion
Apr 6, 2021
Completion
Apr 6, 2021
Results posted
Aug 8, 2022
Last update
Aug 6, 2025

Study contacts

Victoria Butners
study director · Dermavant Sciences GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion